WOCKPHARMA

- Mr. Vinesh Kumar Jairath has ceased to be a Non-Executive Independent Director of the Company. - Cessation is due to the completion of his second consecutive term of five years. - The cessation is effective from the conclusion of business hours on November 9, 2026.

- Mr. Vinesh Kumar Jairath has ceased to be a Non-Executive Independent Director of Wockhardt Limited. - Cessation is effective from November 9, 2026, due to the completion of his second consecutive term of five years.

- Wockhardt Limited's Board of Directors has designated Mr. Sumit Garg, Chief Digital & Information Officer, as Senior Management Personnel (SMP) effective 2nd November, 2026. - Mr. Sumit Garg brings over 30 years of technology and transformation leadership experience across Pharmaceuticals, Life Sciences, FMCG, and Automobile sectors.

- Q2 FY27 Total Revenue grew 24% YoY to ₹969 Cr compared to ₹782 Cr. - EBITDA stood at ₹165 Cr vs ₹160 Cr (₹201 Cr excluding pre-Zaynich launch expenses). - PAT was ₹73 Cr vs ₹82 Cr in Q2 FY26. - Biotech operations surged 68% YoY to ₹252 Cr.

Q2 FY27 Consolidated Revenue ₹969Cr vs ₹782Cr (▲24% YoY) EBITDA ₹173Cr vs ₹178Cr (▼3% YoY) PAT ₹73Cr vs ₹82Cr (▼11% YoY) EBITDA Margin 18% vs 23% (▼500bps)

- The Share Allotment Committee allotted 20,000 equity shares of face value ₹5/- each on 27th October, 2026 under ESOS - 2011. - Paid-up equity share capital increased from ₹81,24,60,845/- to ₹81,25,60,845/-. - Total equity shares increased to 16,25,12,169 shares.

- Trading window for dealing in company shares will close from October 1, 2026. - Window will reopen 48 hours after the declaration of Q2 / half-year ended September 30, 2026 unaudited financial results. - Board meeting date to approve results will be intimated in due course.

- Wockhardt Limited received an Adjudication Order from the Commissioner of Customs, Nhava Sheva-II, JNCH, on August 21, 2026. - Penalties imposed on the company total ₹15 Crore: ₹5 Crore under Section 114 (iii) of the Customs Act, 1962, and a Redemption Fine of ₹10 Crore for mis-declared Active Pharmaceutical Ingredients (API). - An additional ₹1 Crore penalty was levied on a company officer. - The order stems from the mis-classification of an exported API. - The company states the order has no material impact on financials/operations (except the fine) and intends to challenge it.

- Wockhardt announced the launch of the "Wockhardt Antibiotic Academy", an initiative for patient-centric scientific dialogue to tackle Multidrug Resistance (AMR). - The academy is an open scientific learning platform for the medical fraternity to facilitate continuous medical education and knowledge exchange.

- Q1 FY27 Total Revenue ₹929Cr vs ₹738Cr (▲26% YoY) - EBITDA ₹188Cr vs ₹101Cr (▲86% YoY) - PAT ₹107Cr vs ₹(108)Cr (Turnaround from Loss to Profit YoY, with company reporting >100% growth) - EBITDA Margin 20.2% vs 13.7% (▲650bps)

- Q1 FY27 Consolidated Revenue ₹929Cr vs ₹738Cr (▲26% YoY) - EBITDA ₹223Cr vs ₹92Cr (▲142% YoY) - PAT ₹107Cr vs ₹(108)Cr (Turnaround from Loss to Profit) - EBITDA Margin 24% vs 12.5% (▲1150bps)

- The 27th Annual General Meeting (AGM) on August 10, 2026, time has been revised from 3:30 p.m. (IST) to 10:30 a.m. (IST). - An addendum details additional information regarding Related Party Transactions, confirming Audit Committee review and MD/CFO certification.

- Notice of 27th Annual General Meeting (AGM) on August 10, 2026, to adopt FY 2025-26 financial statements. - Agenda includes re-appointment of Ms. Zahabiya Khorakiwala as director and ratification of cost auditor remuneration for FY 2026-27. - Shareholders will vote on revising the Executive Chairman's remuneration and approving material related party transactions. - Approval is sought for raising additional capital up to ₹3,000 Crore via QIP or other offerings. - Also includes modification for redeploying unutilized QIP proceeds of approx ₹162.33 Crore from a November 2024 placement.